Outcomes of kidney transplantation in alport syndrome compared with other forms of renal disease
View/ Open
Full Text
Date
2016-12-05Author
Kelly, Yvelynne P.
Patil, Anish
Wallis, Luke
Murray, Susan
Kant, Saumitra
Kaballo, Mohammed A.
Casserly, Liam
Doyle, Brendan
Dorman, Anthony
O’Kelly, Patrick
Conlon, Peter J.
Metadata
Show full item recordUsage
This item's downloads: 0 (view details)
Cited 5 times in Scopus (view citations)
Recommended Citation
Kelly, Yvelynne P. Patil, Anish; Wallis, Luke; Murray, Susan; Kant, Saumitra; Kaballo, Mohammed A.; Casserly, Liam; Doyle, Brendan; Dorman, Anthony; O’Kelly, Patrick; Conlon, Peter J. (2016). Outcomes of kidney transplantation in alport syndrome compared with other forms of renal disease. Renal Failure 39 (1), 290-293
Abstract
Introduction: Alport syndrome is an inherited renal disease characterized by hematuria, renal failure, hearing loss and a lamellated glomerular basement membrane. Patients with Alport syndrome who undergo renal transplantation have been shown to have patient and graft survival rates similar to or better than those of patients with other renal diseases.
Methods: In this national case series, based in Beaumont Hospital Dublin, we studied the cohort of patients who underwent renal transplantation over the past 33 years, recorded prospectively in the Irish Renal Transplant Registry, and categorized them according to the presence or absence of Alport syndrome. The main outcomes assessed were patient and renal allograft survival.
Results: Fifty-one patients diagnosed with Alport syndrome in Beaumont Hospital received 62 transplants between 1982 and 2014. The comparison group of non-Alport patients comprised 3430 patients for 3865 transplants. Twenty-year Alport patient survival rate was 70.2%, compared to 44.8% for patients with other renal diseases (p = 0.01). Factors associated with patient survival included younger age at transplantation as well as differences in recipient sex, donor age, cold ischemia time, and episodes of acute rejection. Twenty-year graft survival was 46.8% for patients with Alport syndrome compared to 30.2% for those with non-Alport disease (p = 0.11).
Conclusions: Adjusting for baseline differences between the groups, patients with end-stage kidney disease (ESKD) due to Alport syndrome have similar patient and graft survival to those with other causes of ESKD. This indicates that early diagnosis and management can lead to favorable outcomes for this patient cohort.
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland
Related items
Showing items related by title, author, creator and subject.
-
Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial
Amer, H.; Griffin, M. D.; Stegall, M. D.; Cosio, F. G.; Park, W. D.; Kremers, W. K.; Heilman, R. L.; Mazur, M. J.; Hamawi, K.; Larson, T. S.; Kumar, R. (Wiley-Blackwell, 2013-04-19)Postkidney transplant hyperparathyroidism is a significant problem. Vitamin D receptor agonists are known to suppress parathyroid hormone (PTH) secretion. We examined the effect of oral paricalcitol on posttransplant ... -
Differential response of mouse thymic epithelial cell types to ionizing radiation-induced dna damage
Calvo-Asensio, Irene; Barthlott, Thomas; von Muenchow, Lilly; Lowndes, Noel F.; Ceredig, Rhodri (Frontiers Media SA, 2017-04-13)Thymic epithelial cells (TECs) are the main components of the thymic stroma that support and control T-cell development. Preparative regimens using DNA-damaging agents, such as total body irradiation and/or chemotherapeutic ... -
Myeloma patients' experiences of haematopoietic stem cell transplant: A qualitative thematic synthesis
Walpole, Geraldine; Clark, Helen; Dowling, Maura (Elsevier, 2018-05-15)Purpose: The aim of this study was to synthesise all qualitative evidence on the experiences of myeloma patients undergoing haematopoietic stem cell transplant (HSCT).Method: A systematic search strategy was developed and ...